ES2251460T3 - Nuevo uso de (r)-(-)-2-(5-(4-fluorfenil)-3-piridilmetilaminometil)-cromano y sus sales fisiologicamente aceptables. - Google Patents

Nuevo uso de (r)-(-)-2-(5-(4-fluorfenil)-3-piridilmetilaminometil)-cromano y sus sales fisiologicamente aceptables.

Info

Publication number
ES2251460T3
ES2251460T3 ES01902375T ES01902375T ES2251460T3 ES 2251460 T3 ES2251460 T3 ES 2251460T3 ES 01902375 T ES01902375 T ES 01902375T ES 01902375 T ES01902375 T ES 01902375T ES 2251460 T3 ES2251460 T3 ES 2251460T3
Authority
ES
Spain
Prior art keywords
pyridylmethylaminomethyl
chroman
fluorphenyl
physiologically acceptable
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES01902375T
Other languages
English (en)
Spanish (es)
Inventor
Gerd Bartoszyk
Hermann Russ
Christoph Seyfried
Frank Weber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Application granted granted Critical
Publication of ES2251460T3 publication Critical patent/ES2251460T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES01902375T 2000-03-10 2001-02-01 Nuevo uso de (r)-(-)-2-(5-(4-fluorfenil)-3-piridilmetilaminometil)-cromano y sus sales fisiologicamente aceptables. Expired - Lifetime ES2251460T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00104531 2000-03-10
EP00104531 2000-03-10

Publications (1)

Publication Number Publication Date
ES2251460T3 true ES2251460T3 (es) 2006-05-01

Family

ID=8168017

Family Applications (1)

Application Number Title Priority Date Filing Date
ES01902375T Expired - Lifetime ES2251460T3 (es) 2000-03-10 2001-02-01 Nuevo uso de (r)-(-)-2-(5-(4-fluorfenil)-3-piridilmetilaminometil)-cromano y sus sales fisiologicamente aceptables.

Country Status (29)

Country Link
US (1) US7928128B2 (de)
EP (2) EP1299099B1 (de)
JP (1) JP4901046B2 (de)
KR (1) KR100830139B1 (de)
CN (1) CN1188123C (de)
AR (1) AR033807A1 (de)
AT (1) ATE307578T1 (de)
AU (2) AU3022201A (de)
BR (1) BR0109119A (de)
CA (1) CA2402402C (de)
CO (1) CO5271686A1 (de)
CZ (1) CZ301807B6 (de)
DE (1) DE60114419T2 (de)
DK (1) DK1299099T3 (de)
ES (1) ES2251460T3 (de)
HK (1) HK1054198B (de)
HU (1) HU229309B1 (de)
ME (1) MEP5608A (de)
MX (1) MXPA02008800A (de)
MY (1) MY136976A (de)
NO (1) NO329583B1 (de)
PL (1) PL200781B1 (de)
RS (1) RS51316B (de)
RU (1) RU2278663C2 (de)
SI (1) SI1299099T1 (de)
SK (1) SK286933B6 (de)
UA (1) UA73981C2 (de)
WO (1) WO2001068063A2 (de)
ZA (1) ZA200208133B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA73981C2 (en) 2000-03-10 2005-10-17 Merck Patent Gmbh (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane for treatment of extrapyramidal movement disorders (variants), pharmaceutical composition and kit
MXPA04000775A (es) * 2001-07-26 2004-04-20 Merck Patent Ges Mit Baschrank Uso novedoso del 2 -[5-(4-fluorofenil) -3-piridilmetilamino-metil] -cromano y sus sales fisiologicamente aceptables.
PT1427724E (pt) * 2001-09-19 2006-09-29 Merck Patent Gmbh Utilizacao nova de aminometilcromanos substituidos
JP5139275B2 (ja) * 2005-06-21 2013-02-06 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング （ｒ）−（−）−２−［５−（４−フルオロフェニル）−３−ピリジルメチルアミノメチル］クロマンを含有する固体医薬組成物
US9066903B2 (en) 2006-02-28 2015-06-30 The United States Of America As Represented By The Department Of Veterans Affairs Pharmacological treatment of Parkinson's disease
US9248111B2 (en) 2011-03-01 2016-02-02 Pharnext Therapeutic approaches for treating parkinson's disease
US10010515B2 (en) 2011-03-01 2018-07-03 Pharnext Therapeutic approaches for treating Parkinson's disease
CN108937972A (zh) * 2018-06-08 2018-12-07 青岛大学附属医院 一种多特征融合的就诊用户情绪监控方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2364685C3 (de) 1973-12-27 1978-06-15 Beiersdorf Ag, 2000 Hamburg Phenoxyäthylamine
US4438119A (en) * 1982-12-23 1984-03-20 Mead Johnson & Company Method for alleviation of extrapyramidal motor disorders
CA1337429C (en) 1983-12-05 1995-10-24 Guy Rosalia Eugene Van Lommen Derivatives of 2,2'-iminobisethanol
SE460947B (sv) * 1986-08-26 1989-12-11 Lejus Medical Ab En multiple-unit-dos komposition av l-dopa
DE3901814A1 (de) 1988-07-28 1990-02-01 Bayer Ag Substituierte aminomethylzetraline sowie ihre heterocyclischen analoga
ATE145208T1 (de) 1990-07-06 1996-11-15 Yoshitomi Pharmaceutical Kondensierte thiophenverbindungen und deren verwendung
DE4135474A1 (de) 1991-10-28 1993-04-29 Bayer Ag 2-aminomethyl-chromane
US5314888A (en) 1992-02-21 1994-05-24 Trustees Of Tufts College Veterinary method for treating inappropriate elimination of urine in household pets
SI9300097B (en) 1992-02-27 2001-12-31 Janssen Pharmaceutica Nv (benzodioxan, benzofuran or benzopyran) alkylamino) alkyl substituted guanidines
JPH07507058A (ja) * 1992-03-11 1995-08-03 インターニューロン　ファーマシューティカルズ，インコーポレーテッド 大型の中性アミノ酸（ｌｎａａ）の血中濃度の食後変動の低減
DE4226527A1 (de) 1992-08-11 1994-02-17 Merck Patent Gmbh 1,4-Benzodioxanderivate
JPH08503448A (ja) * 1992-12-07 1996-04-16 メレルダウファーマス−ティカルズ インコーポレイテッド ５ｈｔ▲下１▼▲ａ▼受容体アゴニストによる不随意運動の処置
GB9302622D0 (en) 1993-02-10 1993-03-24 Wellcome Found Heteroaromatic compounds
JPH09509398A (ja) * 1993-11-19 1997-09-22 ザ ボード オブ ガヴァナーズ フォー ハイアー エデュケーション，ステイト オブ ロードアイランド アンド プロヴィデンス プランテーションズ オクタヒドロベンゾ［ｆ］キノリン系受容体アゴニストおよびアンタゴニスト
IL114027A (en) 1994-06-08 1999-11-30 Lundbeck & Co As H 4-Phenyl piperazine (piperidine or tetrahydropyridine) derivatives serotinin 5-HT1A and dopamin D2 receptor ligand pharmaceutical compositions containing them
FR2723091B1 (fr) * 1994-07-29 1996-11-08 Esteve Labor Dr Tetrahydropyridine-(6,4-hydroxypiperidine) alkylazoles
SI0707007T1 (en) * 1994-10-14 2002-04-30 Merck Patent Gmbh (R)-(-)-2-(5-(4-fluorophenyl)-3-pyridylmethylaminomethyl)chromane as CNS active agent
US5502080A (en) * 1994-11-01 1996-03-26 Hitzig; Pietr Combined use of dopamine and serotonin agonists in the treatment of allergic disorders
US5554383A (en) 1995-04-06 1996-09-10 Trustees Of Tufts College Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression
US5541199A (en) 1995-06-02 1996-07-30 American Home Products Corporation Chroman-2-ylmethylamino derivatives
GB9514380D0 (en) 1995-07-13 1995-09-13 Knoll Ag Therapeutic agents
AU6517196A (en) 1995-07-13 1997-02-10 Knoll Aktiengesellschaft Piperazine derivatives as therapeutic agents
US5670667A (en) * 1995-07-25 1997-09-23 American Home Products Corporation Chroman-2-ylmethylamino derivatives
US5756521A (en) * 1996-04-03 1998-05-26 American Home Products Corporation Chroman-2-ylmethylamino derivatives
DE19648384A1 (de) * 1996-11-22 1998-05-28 Merck Patent Gmbh Fluorene, Dibenzofurane und Dibenzothiophene
DE69819266T2 (de) 1997-09-02 2004-07-29 Duphar International Research B.V. Piperidin- und Piperazin Derivate als 5-HT1-Rezeptor-Agonisten
EP0900792B1 (de) 1997-09-02 2003-10-29 Duphar International Research B.V Piperidin- und Piperazin Derivate als 5-HT1-Rezeptor-Agonisten
DE19751949A1 (de) 1997-11-24 1999-05-27 Bayer Ag Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration
EP1061924A1 (de) 1998-03-09 2000-12-27 Trustees Of Tufts College Behandlung von compulsiven verhalten bei menschen und tieren
ID25651A (id) * 1998-03-17 2000-10-19 Pfizer Prod Inc Senyawa-senyawa bisiklo [2.2.1] heptana dan senyawa-senyawa yang terkait
FR2781671A1 (fr) * 1998-07-28 2000-02-04 Synthelabo Compositions pharmaceutiques contenant un inhibiteur de la recapture de la serotonine et leur application en therapeutique
UA71590C2 (en) 1998-11-13 2004-12-15 Duphar Int Res Piperazine and piperidine derivatives
UA73981C2 (en) 2000-03-10 2005-10-17 Merck Patent Gmbh (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane for treatment of extrapyramidal movement disorders (variants), pharmaceutical composition and kit

Also Published As

Publication number Publication date
WO2001068063A2 (en) 2001-09-20
PL356428A1 (en) 2004-06-28
UA73981C2 (en) 2005-10-17
ZA200208133B (en) 2004-04-01
CA2402402A1 (en) 2001-09-20
DE60114419T2 (de) 2006-07-27
YU67402A (sh) 2006-01-16
AU3022201A (en) 2001-09-24
MXPA02008800A (es) 2003-02-12
BR0109119A (pt) 2003-06-03
CN1416344A (zh) 2003-05-07
HUP0300079A2 (en) 2003-05-28
MY136976A (en) 2008-12-31
WO2001068063A3 (en) 2002-05-10
EP1645273A2 (de) 2006-04-12
EP1299099B1 (de) 2005-10-26
NO329583B1 (no) 2010-11-15
CA2402402C (en) 2013-01-22
RU2278663C2 (ru) 2006-06-27
DK1299099T3 (da) 2006-03-06
HK1054198A1 (en) 2003-11-21
JP2004522692A (ja) 2004-07-29
AU2001230222B2 (en) 2005-03-17
RS51316B (sr) 2010-12-31
EP1299099A2 (de) 2003-04-09
HK1054198B (zh) 2005-05-20
US7928128B2 (en) 2011-04-19
SK12642002A3 (sk) 2003-02-04
NO20024291D0 (no) 2002-09-09
JP4901046B2 (ja) 2012-03-21
DE60114419D1 (de) 2005-12-01
US20030181486A1 (en) 2003-09-25
MEP5608A (xx) 2010-02-10
CZ301807B6 (cs) 2010-06-30
PL200781B1 (pl) 2009-02-27
AU2001230222C1 (en) 2005-09-22
ATE307578T1 (de) 2005-11-15
KR100830139B1 (ko) 2008-05-20
EP1645273A3 (de) 2006-04-19
CN1188123C (zh) 2005-02-09
CO5271686A1 (es) 2003-04-30
KR20030016236A (ko) 2003-02-26
RU2002127006A (ru) 2004-03-27
SK286933B6 (sk) 2009-07-06
SI1299099T1 (sl) 2006-04-30
AR033807A1 (es) 2004-01-07
CZ20022951A3 (cs) 2003-01-15
NO20024291L (no) 2002-09-09
HU229309B1 (en) 2013-10-28

Similar Documents

Publication Publication Date Title
ES2251460T3 (es) Nuevo uso de (r)-(-)-2-(5-(4-fluorfenil)-3-piridilmetilaminometil)-cromano y sus sales fisiologicamente aceptables.
ES2280602T3 (es) Uso de 2-(5-(4-fluorofenil)-3-piridilmetilaminometil)-cromano y sus sales fisiologicamente aceptables.
AU2002355170A1 (en) Novel use of 2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts
AU2001230222A1 (en) Novel use of (R)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]- chromane and its physiologically acceptable salts
ES2272771T3 (es) Uso de aminometil cromanos sustituidos en el tratamiento de transtornos extrapirimidales del movimiento.
AU2002331220A1 (en) Novel use of substituted aminomethyl chromans for the treatment of movement disorder and of adverse effects induced by drugs administered to treat extrapyramidal movement disorders
ZA200401592B (en) Novel use of 2-[5- (4-fluorophenyl)-3-pyridylmethylaminomethyl} -chromane and its physiologically acceptable salts